Molecular imaging & peptide receptor radionuclide therapy

Advances in Pulmonary Neuroendocrine Tumor Management ◽

10.2217/ebo.12.80 ◽

2013 ◽

pp. 20-34

Author(s):

Richard P Baum ◽

Harshad R Kulkarni ◽

Dieter Hörsch

Keyword(s):

Molecular Imaging ◽

Radionuclide Therapy ◽

Peptide Receptor Radionuclide Therapy ◽

Peptide Receptor

Download Full-text

Optimization of combined temozolomide and peptide receptor radionuclide therapy (PRRT) in mice after multimodality molecular imaging studies

EJNMMI Research ◽

10.1186/s13550-015-0142-y ◽

2015 ◽

Vol 5 (1) ◽

Cited By ~ 6

Author(s):

Sander M. Bison ◽

Joost C. Haeck ◽

K. Bol ◽

S. J. Koelewijn ◽

H. C. Groen ◽

...

Keyword(s):

Molecular Imaging ◽

Radionuclide Therapy ◽

Peptide Receptor Radionuclide Therapy ◽

Imaging Studies ◽

Peptide Receptor

Download Full-text

FRI-13 Molecular imaging (Gallium-68 SMS-receptor PET/CT) and peptide receptor radionuclide therapy (PRRNT) of GEP-neuroendocrine neoplasms (GEP-NEP)

Digestive and Liver Disease ◽

10.1016/s1590-8658(13)60655-6 ◽

2013 ◽

Vol 45 ◽

pp. S246

Author(s):

R.P. Baum

Keyword(s):

Molecular Imaging ◽

Radionuclide Therapy ◽

Peptide Receptor Radionuclide Therapy ◽

Neuroendocrine Neoplasms ◽

Peptide Receptor ◽

Pet Ct ◽

Gallium 68

Download Full-text

From Outside to Inside? Dose-Dependent Renal Tubular Damage After High-Dose Peptide Receptor Radionuclide Therapy in Rats Measured with In Vivo 99mTc-DMSA-SPECT and Molecular Imaging

Cancer Biotherapy & Radiopharmaceuticals ◽

10.1089/cbr.2006.353 ◽

2007 ◽

Vol 22 (1) ◽

pp. 40-49 ◽

Cited By ~ 17

Author(s):

Flavio Forrer ◽

Edgar Rolleman ◽

Magda Bijster ◽

Marleen Melis ◽

Bert Bernard ◽

...

Keyword(s):

Molecular Imaging ◽

Radionuclide Therapy ◽

Peptide Receptor Radionuclide Therapy ◽

High Dose ◽

Tubular Damage ◽

Renal Tubular Damage ◽

Peptide Receptor ◽

Renal Tubular ◽

Dose Dependent

Download Full-text

Combined use of peptide receptor radionuclide therapy and metronomic chemotherapy in neuroendocrine tumors: a possible choice driven by nuclear medicine molecular imaging

European Journal of Nuclear Medicine and Molecular Imaging ◽

10.1007/s00259-021-05330-2 ◽

2021 ◽

Author(s):

Fabio Minutoli ◽

Riccardo Laudicella ◽

Irene A. Burger ◽

Sergio Baldari

Keyword(s):

Nuclear Medicine ◽

Molecular Imaging ◽

Neuroendocrine Tumors ◽

Radionuclide Therapy ◽

Peptide Receptor Radionuclide Therapy ◽

Metronomic Chemotherapy ◽

Peptide Receptor ◽

Combined Use

Download Full-text

Correlation and discordance of tumour proliferation index and molecular imaging characteristics and their implications for treatment decisions and outcome pertaining to peptide receptor radionuclide therapy in patients with advanced neuroendocrine tumour

Nuclear Medicine Communications ◽

10.1097/mnm.0000000000000321 ◽

2015 ◽

Vol 36 (8) ◽

pp. 766-774 ◽

Cited By ~ 9

Author(s):

Sandip Basu ◽

Rohit Ranade ◽

Pradeep Thapa

Keyword(s):

Molecular Imaging ◽

Radionuclide Therapy ◽

Neuroendocrine Tumour ◽

Peptide Receptor Radionuclide Therapy ◽

Treatment Decisions ◽

Proliferation Index ◽

Peptide Receptor ◽

Imaging Characteristics ◽

Tumour Proliferation

Download Full-text

Safety and efficacy of sequential local ablative therapy and peptide receptor radionuclide therapy in patients with neuroendocrine neoplasms and high tumor load; An analysis of 50 sequential patients

Experimental and Clinical Endocrinology & Diabetes ◽

10.1055/s-0035-1547651 ◽

2015 ◽

Vol 122 (03) ◽

Author(s):

D Hörsch

Keyword(s):

Radionuclide Therapy ◽

Peptide Receptor Radionuclide Therapy ◽

Neuroendocrine Neoplasms ◽

Safety And Efficacy ◽

Ablative Therapy ◽

Peptide Receptor ◽

Local Ablative Therapy ◽

Tumor Load

Download Full-text

DNA damage response (DDR) and repair kinetics predict treatment response in patients receiving Lu-177-DOTA-TATE peptide receptor radionuclide therapy for advanced gastro-entero-pancreatic neuroendocrine tumors

10.1055/s-0040-1708134 ◽

2020 ◽

Author(s):

T Derlin ◽

N Bogdanova ◽

F Ohlendorf ◽

R Werner ◽

H Christiansen ◽

...

Keyword(s):

Dna Damage ◽

Treatment Response ◽

Neuroendocrine Tumors ◽

Dna Damage Response ◽

Radionuclide Therapy ◽

Peptide Receptor Radionuclide Therapy ◽

Pancreatic Neuroendocrine Tumors ◽

Peptide Receptor ◽

Damage Response ◽

Predict Treatment Response

Download Full-text

Two Decades of THERANOSTICS in Neuroendocrine Tumors - Past, Presence and Future of Peptide Receptor Radionuclide Therapy (PRRT)

Endocrine Abstracts ◽

10.1530/endoabs.47.oc7 ◽

2016 ◽

Author(s):

Richard Baum

Keyword(s):

Neuroendocrine Tumors ◽

Radionuclide Therapy ◽

Peptide Receptor Radionuclide Therapy ◽

Peptide Receptor

Download Full-text

Lanreotide depot/autogel before, during, and after peptide receptor radionuclide therapy (PRRT) in advanced neuroendocrine tumors (NETs): Data from the PRELUDE study

Endocrine Abstracts ◽

10.1530/endoabs.60.oc2 ◽

2018 ◽

Author(s):

Vikas Prasad ◽

Raj Srirajaskanthan ◽

Christos Toumpanakis ◽

Chiara Maria Grana ◽

Sergio Baldari ◽

...

Keyword(s):

Neuroendocrine Tumors ◽

Radionuclide Therapy ◽

Peptide Receptor Radionuclide Therapy ◽

Peptide Receptor

Download Full-text

Peptide receptor radionuclide therapy (PRRT) in patients with giant aggressive pituitary tumors: experience of an Italian referral center and review of literature

Endocrine Abstracts ◽

10.1530/endoabs.63.gp239 ◽

2019 ◽

Author(s):

Giuseppe Giuffrida ◽

Francesco Ferrau ◽

Riccardo Laudicella ◽

Oana Ruxandra Cotta ◽

Antonio Vento ◽

...

Keyword(s):

Radionuclide Therapy ◽

Pituitary Tumors ◽

Peptide Receptor Radionuclide Therapy ◽

Review Of Literature ◽

Peptide Receptor ◽

Referral Center

Download Full-text